Scholar Rock Announces Upcoming Departure of Chief Financial Officer
27 août 2019 16h30 HE
|
Scholar Rock
CAMBRIDGE, Mass., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical stage biopharmaceutical company, announced today that its Chief Financial Officer,...
Scholar Rock Reports Second Quarter 2019 Financial Results and Highlights Business Progress
14 août 2019 07h30 HE
|
Scholar Rock
Enrollment on track in the TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy for preliminary PK/PD results by year-endPresented positive final results...
Scholar Rock to Present at the 2019 Wedbush PacGrow Healthcare Conference
07 août 2019 16h01 HE
|
Scholar Rock
CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock in Public Offering
02 juil. 2019 16h05 HE
|
Scholar Rock
CAMBRIDGE, Mass., July 02, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock Announces Pricing of Public Offering of Common Stock
19 juin 2019 18h07 HE
|
Scholar Rock
CAMBRIDGE, Mass., June 19, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock to Present at the 2019 BMO Prescriptions for Success Healthcare Conference
19 juin 2019 07h30 HE
|
Scholar Rock
CAMBRIDGE, Mass., June 19, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock Announces Proposed Public Offering of Common Stock
18 juin 2019 16h50 HE
|
Scholar Rock
CAMBRIDGE, Mass., June 18, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers
03 juin 2019 16h05 HE
|
Scholar Rock
- SRK-015 was well-tolerated in healthy volunteers across all tested doses, supporting evaluation in the ongoing Phase 2 TOPAZ trial in Spinal Muscular Atrophy (SMA) - Pharmacodynamic results...
Scholar Rock to Present at the Jefferies 2019 Global Healthcare Conference
28 mai 2019 16h05 HE
|
Scholar Rock
CAMBRIDGE, Mass., May 28, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock Reports First Quarter 2019 Financial Results and Highlights Business Progress
14 mai 2019 16h05 HE
|
Scholar Rock
Commenced patient enrollment and dosing in TOPAZ, the Phase 2 clinical trial for SRK-015 in Type 2 and Type 3 Spinal Muscular Atrophy (SMA) Presented additional preclinical data from the SRK-181...